Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors
October 27, 2020 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Artificial Intelligence in Drug Discovery Market To Reach USD 2.13 Billion By 2027 | Reports and Data
April 23, 2020 15:00 ET
|
Reports and Data
New York, April 23, 2020 (GLOBE NEWSWIRE) -- According to Reports and Data, the Artificial Intelligence in Drug Discovery Market was valued at USD 253.8 million in 2019 and is expected to reach USD...
Neurodegenerative Diseases Drugs Market to Reach US$ 62,786.2 Mn by 2026, Biogen and F. Hoffmann-La Roche Ltd Cover More than Half of the Share: Fortune Business Insights
July 25, 2019 11:25 ET
|
Fortune Business Insights
Pune, July 25, 2019 (GLOBE NEWSWIRE) -- The global neurodegenerative diseases drugs market’s growth is expected to derive growth from the rising prevalence of neurodegenerative diseases...
Servier backs an American startup at LabCentral in the field of mitochondrial health for neurodegenerative and rare diseases
November 14, 2018 02:00 ET
|
LabCentral
PARIS, France and CAMBRIDGE, Mass. USA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Servier, an independent international pharmaceutical laboratory, and LabCentral, a well-known launchpad for innovative life...
DiamiR Announces Oral Presentation at AD/PD(TM) 2017
March 29, 2017 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 29, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Samuil...
DiamiR Awarded $2.75M Grant for Development of CogniMIR(TM) for Early Detection of Alzheimer's Disease
March 15, 2017 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 15, 2017) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...
DiamiR Announces SBIR Phase I Award for Aging Program
June 07, 2016 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - June 07, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests, announced today that the National Institute on Aging (NIA) of the...
Cantabio Pharmaceuticals Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with NovAliX
April 12, 2016 12:00 ET
|
Cantabio Pharmaceuticals Inc.
PALO ALTO, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) announced today a new preclinical therapeutic program for Alzheimer’s Disease which it is...
CANTABio and Gardedam Therapeutics complete Merger to Tackle Development of Novel Therapeutics for Alzheimer's and Parkinson's Disease
December 21, 2015 13:00 ET
|
Cantabio Pharmaceuticals Inc.
PALO ALTO, Calif., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. ("Cantabio") (OTCQB:CTBO) is pleased to announce the completion of its reverse merger (the "Merger") with...
DiamiR Announces $1.5M SBIR Phase II Funding for Further Evaluation of the microRNA Biomarkers for Early Detection of Alzheimer's Disease
March 16, 2015 08:02 ET
|
DiamiR
MONMOUTH JUNCTION, NJ--(Marketwired - March 16, 2015) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...